A comparative study of serum adiponectin levels in patients of acute coronary syndrome with and without central obesity

Shashank R. Tiwari, Lokesh S., Arunprasath P., Arun Kumar R.


Background: Coronary artery disease burden has been on a rise globally with it emerging as the principle cause of death even in the Indian subcontinent. Serum adiponectin has recently gained interest due to its close relation with atherosclerotic CAD and Metabolic syndrome. The levels of serum adiponectin are reduced in ACS. There is a paucity of studies in South Indian population comparing the effect of central obesity in patient with ACS. The aim of the present endeavour was to study the association of serum adiponectin in risk evaluation of patient with acute coronary syndrome with and without central obesity

Methods: The study was conducted in a tertiary center in patient who presented with first time ACS they were grouped into two groups based on the presence and absence of central obesity. Central obesity was defined on the basis of waist to hip ratio. Serum adiponectin levels were estimated in both the groups using ELISA method. The results were statistically analyzed using t- test.

Results: Authors concluded that the mean age of patients presenting first time with ACS was 55±12years in both the group. There was a significantly raised LDL and Total Cholesterol (TC) level in patient with central obesity.

 The estimated serum adiponectin level was reduced in both the group with more significant reduction in group with central obesity. The mean adiponectin level in CAD patients with central obesity was 2.326±1.437µg/ml as compared to 3.486±1.6999μg/ml in patients without central obesity, which was statistically significant (p value <0.0049).

Conclusions: Authors concluded that serum adiponectin levels were reduced in both the group with ACS with a further reduction in patient with central obesity. It was also observed that there was a significant relation between adiponectin level and visceral fat as compared to superficial fat, as adiponectin was significantly reduced in patient higher waist-hip ratio.


Adiponectin, Acute coronary syndrome, Metabolic syndrome

Full Text:



Rao M, Xavier D, Devi P, Sigamani A, Faruqui A, Gupta R, et al. Prevalence, treatments and outcomes of coronary artery disease in Indians: a systematic review. Indian Heart J. 2015 Jul;67(4):302-10.

WHO. Prevention of Recurrences of Myocardial Infarction and Stroke Study. WHO. Available at:

Bhutta ZA. The million death study in India: Can it help in monitoring the millennium development goals? PLoS Med. 2006 February 14; 3(2):e103.

Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiology Study (CURES-4). Metab - Clin Exp. 2005 Apr 1;54(4):476-81.

Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006 May;8(3):264-80.

Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, et al. Adiponectin and Coronary Heart Disease. Circulation. 2006 Aug 15;114(7):623-9.

Mittal A, Gupta MD, Meennahalli Palleda G, Vyas A, Tyagi S. Relationship of Plasma Adiponectin Levels with Acute Coronary Syndromes and Coronary Lesion Severity in North Indian Population. ISRN Cardiol. 2013;2013:1-5.

Jain R, Dwivedi S, Aggarwal A. Adiponectin, central obesity and carotidintima media thickness in coronary artery disease patients. Preventive Cardiology. 2014 May;3(4):555-61.

Oliveira GB de F, França JÍD, Piegas LS. Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol. 2013 Nov;101(5):399-409.

Di Chiara T, Argano C, Corrao S, Scaglione R, Licata G. Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome. J Nutr Metab. 2011 Oct 16;2012:e175245.